Contraindications: Hypersensitivity to domperidone or to other components. A condition in which stimulation of gastric motility can be dangerous, i.e. gastro-intestinal bleeding, mechanical obstruction or perforation. Prolactinoma. In patients with moderate or severe hepatic impairment. In patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure.

Precautions: The use in children, as well as during pregnancy and lactation only on prescription!

Pregnancy and Lactation: When administered to animals in doses up 160mg/kg/day, domperidone had no teratogenic effects. However, as most of the drugs Peptomet should be administered during the first trimester of pregnancy only if its use is justified by the expected therapeutic benefit.

Domperidone is excreted in human milk and breast-fed infants receive less than 0.1 % of the maternal weight-adjusted dose. Occurrence of adverse effects, in particular cardiac effects cannot be excluded after exposure via breast milk. A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from domperidone therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Packing: 10 tablets in a blister. 3 blisters (30 tablets) in a cardboard box along with a leaflet.

Produced by: "Remedica", Cyprus.
See also: http://www.remedica.eu